Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals

Novo Nordisk's stock experienced a significant drop of more than 5% on Monday after the company failed to satisfy Wall Street expectations during its capital markets day. The primary issue lies in the company's inability to provide more detailed information on near-term growth targets amidst intense competition in the weight loss drug market.

Novo Nordisk has set a target of generating over $23 billion in pipeline sales by 2035, with plans to introduce more than five potential multi-blockbuster drugs by the end of the decade. CEO Mike Doustdar acknowledged the unprecedented level of competition, stating that Novo Nordisk has transitioned from operating in a duopoly to facing competition from nearly every major pharmaceutical company.

In response, Doustdar emphasized the need for the company to adapt to this new competitive landscape. As CEO since August 2025, Doustdar has dedicated 33 years of his career to Novo Nordisk, starting as an office clerk in Vienna in 1992. Recently, Doustdar has focused on enhancing the marketing of Wegovy while accelerating the development of its pill form, which underperformed in the latest quarter.

The CEO is also intensifying R&D efforts to tackle future patent expirations and bolster the company's long-term prospects. Doustdar expressed his aspirations for a post-patent cliff era where Novo Nordisk dominates the semaglutide market, highlighting the company's current status as the largest generic insulin producer globally.

To address future challenges, Doustdar is exploring strategic partnerships and acquisitions, aiming to complement the company's existing strengths.